Skip to main content
. 2016 Jul 22;113(32):9015–9020. doi: 10.1073/pnas.1603883113

Fig. S5.

Fig. S5.

RMS13-R cells remain sensitive to a diverse spectrum of cytotoxic compounds. RMS13 and RMS13-R cells were seeded into 96-well plates and treated for 72 h with (A) MAL3-101, (B) bortezomib, (C) Vernalis 155008, (D) thapsigargin, (E) actinomycin D, (F) homoharringtonine, (G) vincristine, or (H) paclitaxel, representing inhibitors of different nodes of the proteostasis networks and conventional chemotherapeutic agents active in RMS. Viability was measured by CellTiter-Glo. The data shown represent the means of three independent experiments.